| Preexposure chemoprophylaxis for HIV prevention in men who have sex with men RM Grant, JR Lama, PL Anderson, V McMahan, AY Liu, L Vargas, ... New England Journal of Medicine 363 (27), 2587-2599, 2010 | 5822 | 2010 |
| Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study RM Grant, PL Anderson, V McMahan, A Liu, KR Amico, M Mehrotra, ... The Lancet infectious diseases 14 (9), 820-829, 2014 | 1279 | 2014 |
| Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men PL Anderson, DV Glidden, A Liu, S Buchbinder, JR Lama, JV Guanira, ... Science translational medicine 4 (151), 151ra125-151ra125, 2012 | 1066 | 2012 |
| Preexposure prophylaxis for HIV infection integrated with municipal-and community-based sexual health services AY Liu, SE Cohen, E Vittinghoff, PL Anderson, S Doblecki-Lewis, O Bacon, ... JAMA internal medicine 176 (1), 75-84, 2016 | 654 | 2016 |
| Cabotegravir for HIV prevention in cisgender men and transgender women RJ Landovitz, D Donnell, ME Clement, B Hanscom, L Cottle, L Coelho, ... New England Journal of Medicine 385 (7), 595-608, 2021 | 463 | 2021 |
| Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III … E Abraham, PF Laterre, J Garbino, S Pingleton, T Butler, T Dugernier, ... Critical care medicine 29 (3), 503-510, 2001 | 395 | 2001 |
| Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised … KH Mayer, JM Molina, MA Thompson, PL Anderson, KC Mounzer, ... The Lancet 396 (10246), 239-254, 2020 | 333 | 2020 |
| Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure JR Castillo-Mancilla, JH Zheng, JE Rower, A Meditz, EM Gardner, ... AIDS research and human retroviruses 29 (2), 384-390, 2013 | 311 | 2013 |
| An HIV preexposure prophylaxis demonstration project and safety study for young MSM SG Hosek, B Rudy, R Landovitz, B Kapogiannis, G Siberry, B Rutledge, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 74 (1), 21-29, 2017 | 292 | 2017 |
| Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm JE Haberer, DR Bangsberg, JM Baeten, K Curran, F Koechlin, KR Amico, ... Aids 29 (11), 1277-1285, 2015 | 280 | 2015 |
| The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV‐infected patients JJ Kiser, ML Carten, CL Aquilante, PL Anderson, P Wolfe, TM King, ... Clinical Pharmacology & Therapeutics 83 (2), 265-272, 2008 | 246 | 2008 |
| Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial S Delany-Moretlwe, JP Hughes, P Bock, SG Ouma, P Hunidzarira, ... The Lancet 399 (10337), 1779-1789, 2022 | 239 | 2022 |
| Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection PL Anderson, JJ Kiser, EM Gardner, JE Rower, A Meditz, RM Grant Journal of antimicrobial chemotherapy 66 (2), 240-250, 2011 | 231 | 2011 |
| Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy PL Anderson, AY Liu, JR Castillo-Mancilla, EM Gardner, SM Seifert, ... Antimicrobial agents and chemotherapy 62 (1), 10.1128/aac. 01710-17, 2018 | 226 | 2018 |
| Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States SG Hosek, RJ Landovitz, B Kapogiannis, GK Siberry, B Rudy, B Rutledge, ... JAMA pediatrics 171 (11), 1063-1071, 2017 | 208 | 2017 |
| Antiretroviral medication adherence and the development of class-specific antiretroviral resistance EM Gardner, WJ Burman, JF Steiner, PL Anderson, DR Bangsberg Aids 23 (9), 1035-1046, 2009 | 208 | 2009 |
| Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients JJ Kiser, CL Aquilante, PL Anderson, TM King, ML Carten, CV Fletcher JAIDS Journal of Acquired Immune Deficiency Syndromes 47 (3), 298-303, 2008 | 203 | 2008 |
| Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study PL Anderson, J Lamba, CL Aquilante, E Schuetz, CV Fletcher JAIDS Journal of Acquired Immune Deficiency Syndromes 42 (4), 441-449, 2006 | 199 | 2006 |
| The cellular pharmacology of nucleoside-and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities PL Anderson, TN Kakuda, KA Lichtenstein Clinical Infectious Diseases 38 (5), 743-753, 2004 | 199 | 2004 |
| Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial K Mulligan, DV Glidden, PL Anderson, A Liu, V McMahan, P Gonzales, ... Clinical infectious diseases 61 (4), 572-580, 2015 | 188 | 2015 |
